This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Aveanna Healthcare (AVAH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aveanna Healthcare (AVAH) and AxoGen (AXGN) have performed compared to their sector so far this year.
BiomX Stock Gains From Favorable Study Data Presentation on BX004
by Zacks Equity Research
PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept. 28.
Innovation Aids Alcon Stock's Growth Despite Macroeconomic Troubles
by Zacks Equity Research
Banking on strong sales of its contact lenses and ocular health products, ALC is registering solid growth within Vision Care.
DGX Stock to Benefit From New Partnership With Sentara Health Plans
by Zacks Equity Research
Quest Diagnostics extends services in Virginia and Florida via a partnership with Sentara Health Plans.
VERO Stock Likely to Get Support From New Regulatory Nod in Australia
by Zacks Equity Research
The latest approval for Venus Concept in Australia reinforces its position as a global player in the aesthetic technology space.
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
by Zacks Equity Research
Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the United States.
QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity
by Zacks Equity Research
QIAGEN launches 100 new assays for QIAcuity. The newly launched assays are now available through the company???s GeneGlobe platform.
TMO Stock to Gain From Expanded Bioanalytical Services in Sweden
by Zacks Equity Research
Thermo Fisher's PPD arm unveils a new facility in Sweden, expanding its bioanalytical capabilities.
Reasons to Retain EYE Stock in Your Portfolio for Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust market expansion of the Owned and Host segment bode well for National Vision.
Is Teleflex Stock a Smart Option for Your Portfolio Right Now?
by Zacks Equity Research
TFX instils optimism with its robust performance in the Interventional category and potential in Asia.
BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?
by Zacks Equity Research
Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective for LBBA pacing.
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
by Zacks Equity Research
Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
Should You Continue to Retain MYGN Stock in Your Portfolio?
by Zacks Equity Research
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.
PEN Stock to Gain From CE Mark Approval for its CAVT Technologies
by Zacks Equity Research
Penumbra receives the CE Mark approval for Lightning Flash 2.0 and Lightning Bolt 7 in Europe.
IINN Stock Gains on Second US Patent Approval for VORTX System
by Zacks Equity Research
Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for the INGN stock.
PAHC Stock Gains From Innovation, Market Expansion Goal
by Zacks Equity Research
Phibro Animal Health's nutritional product offerings, such as OmniGen-AF and Animate, are being increasingly used in the global dairy industry.
Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?
by Zacks Equity Research
QIAGEN and Bio-Manguinhos/Fiocruz team up to enhance malaria and dengue detection in Brazil's national screening programs.
Owens & Minor Stock to Gain From New Collaboration With Google Cloud
by Zacks Equity Research
OMI announces partnership with Google Cloud to enhance existing QSight capabilities.
Should You Continue to Retain OMCL Stock in Your Portfolio Now?
by Zacks Equity Research
Omnicell is well-placed for growth in the upcoming quarters owing to its progress in achieving the Autonomous Pharmacy goal.
LH Stock Expected to Gain From the Ballad Health Acquisition Deal
by Zacks Equity Research
Labcorp has reached an agreement to purchase select outreach laboratory services from Ballad Health.
HSIC Stock Likely to Get a Boost From New Henry Schein One Launches
by Zacks Equity Research
Henry Schein's dental software arm unveils Dentrix Eligibility offerings to elevate the insurance verification process.
CRL Stock May Benefit From New Neuroscience Research Collaboration
by Zacks Equity Research
Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now
by Zacks Equity Research
Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.